Hormones and prostate cancer: current perspectives and future directions.
about
Coumaphos exposure and incident cancer among male participants in the Agricultural Health Study (AHS)Proteomics of rat prostate lobes treated with 2-N-hydroxylamino-1-methyl-6-phenylimidazo[4,5-b]pyridine, 5alpha-dihydrotestosterone, individually and in combinationA nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).A functional C-G polymorphism in the CYP7B1 promoter region and its different distribution in Orientals and Caucasians.Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of korean men.Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.Androgen deprivation induces rapid involution and recovery of human prostate vasculaturePotassium channel subtypes as molecular targets for overactive bladder and other urological disorders.A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trialsEthnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.Novel biomarkers for risk of prostate cancer: results from a case-control study.Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.The role of testosterone in the pathogenesis of prostate cancer.Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men.Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels.Finasteride.The targets of curcumin.Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.Bringing GC-MS profiling of steroids into clinical applications.Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.Interleukin-6 regulates androgen synthesis in prostate cancer cells.Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.Serum prostate-specific antigen levels in men with prediabetes: a cross-sectional study.Possible relations between oxidative damage and apoptosis in benign prostate hyperplasia and prostate cancer patients.The influence of occupational exposure to pesticides, polycyclic aromatic hydrocarbons, diesel exhaust, metal dust, metal fumes, and mineral oil on prostate cancer: a prospective cohort study.PSA mass as a marker of prostate cancer progression after radical prostatectomy.Serum Testosterone, 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders.Genome-wide association study of sex hormones, gonadotropins and sex hormone-binding protein in Chinese men.Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival.Long-term inhibition of 5-alpha reductase and aromatase changes the cellular and extracellular compartments in gerbil ventral prostate at different postnatal ages.Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer.Polymorphism of cytochrome P450 2B6 and prostate cancer risk: a significant association in a Japanese population.Androgens modulate male-derived endothelial cell homeostasis using androgen receptor-dependent and receptor-independent mechanisms.Maximizing outcomes in genitourinary cancers across the treatment continuum.Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men.
P2860
Q28394004-5DC058A3-3E23-4592-97B8-002E1DEF4128Q28565574-E5A9AFA5-E96E-4EE0-B31F-88D2CF3D9C2CQ34142018-9B6FB9E7-9CCB-41B7-A188-F8ED727AED23Q34303925-82B5C50C-DC02-48C2-943A-D6C43FBB4390Q34468676-DEAD1D88-43FE-496B-AAF6-5577182C3FCFQ34621809-09436619-212D-49E5-868E-0A19900672CDQ35760385-7C9DB89C-EEBE-4D75-9FFF-D5A764FF399BQ35911129-F2044071-EE2D-4B26-9437-9F05B8724A33Q36102847-0CB45A12-5049-4AA3-802E-6525B9049EB0Q36254416-11A9C492-AA63-4A19-A79A-9764BD4B8D3DQ36381291-8CE26B04-B3ED-4F75-AA98-8595B27FDCE0Q36639953-633A3918-7824-40C0-AA4E-B5BEBFAB90D6Q36758880-F88CA429-AF0F-43A8-9716-2CD858070EDAQ36987110-0ECFF638-8247-47DD-883C-B8A86D6ABB7FQ37020542-A4C3BBFA-1AA3-46B5-A719-0929CE5ACF23Q37145218-8AF91062-FAF9-4FA3-BFAB-8D582DEFF812Q37189990-D75920EA-2DA3-440A-ADB3-8099DB32F871Q37605856-53E91226-AE11-49C2-8907-273DFEE601CAQ37763952-D668D9F9-53B7-4A99-B3A7-7476C37848CAQ37800949-CEA9C6CA-5302-4786-8AE6-B55FAFA1C574Q37818297-DE4BAB6D-2E74-4080-9FFF-9802CE3D87AAQ38095223-13C570B0-6748-41DD-8DF6-5864C2679933Q38180392-550CC70D-0C9E-446F-8478-C9DFECCA1620Q38223309-DBAA17A9-3590-489F-802B-D6455A09256EQ39168087-009F0F8F-F5F8-424C-A16B-ED1AE41584C8Q39819739-C2FFCB42-E4F2-4B39-979B-C7735E6EE535Q39842237-8AF6F584-9B28-4D67-BB40-680DC0E072D1Q41340371-51D3BFBB-3DE9-4745-AF57-0D328892969DQ41390358-A662973F-23E6-4C0B-A1B6-6577ADCEBFE5Q42245001-5A9D6EB2-7484-4C8D-9979-F1B74669C94BQ42415229-92DD5454-BB4E-427B-AC5B-79F7A71D7E4FQ42540165-9EFB01C4-62AD-44DD-841B-D70464C7DA56Q42618966-1F18A7E5-7028-40AA-997C-C0D88C80EDB4Q43479315-BBC8F677-B878-461F-A5A4-240A80E95AE6Q45782221-540D3133-C14D-4442-AD43-1F673A55830DQ46320236-760A453F-449C-46C5-89A2-642A2697E98CQ47853637-1BE2E90F-775B-46F9-90D2-E517FF9B48F3Q47993005-9F993531-FA41-4D6A-A5A8-57FD4463F031Q50246373-C82F959C-0515-4A10-863C-E7910171DFDDQ50940566-294CC764-81A1-4BB5-8EFC-DCAB39AC1036
P2860
Hormones and prostate cancer: current perspectives and future directions.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Hormones and prostate cancer: current perspectives and future directions.
@ast
Hormones and prostate cancer: current perspectives and future directions.
@en
Hormones and prostate cancer: current perspectives and future directions.
@nl
type
label
Hormones and prostate cancer: current perspectives and future directions.
@ast
Hormones and prostate cancer: current perspectives and future directions.
@en
Hormones and prostate cancer: current perspectives and future directions.
@nl
prefLabel
Hormones and prostate cancer: current perspectives and future directions.
@ast
Hormones and prostate cancer: current perspectives and future directions.
@en
Hormones and prostate cancer: current perspectives and future directions.
@nl
P2860
P356
P1433
P1476
Hormones and prostate cancer: current perspectives and future directions.
@en
P2093
Ann W Hsing
Frank Z Stanczyk
P2860
P304
P356
10.1002/PROS.10108
P577
2002-08-01T00:00:00Z